Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus resinosa pollen is a diagnostic allergen extract derived from the red pine tree (*Pinus resinosa*), a species native to North America. It is primarily utilized in clinical settings as a diagnostic agent to identify patients with allergic sensitivities to red pine pollen through skin testing procedures, such as skin prick or intradermal tests. The extract works by interacting with allergen-specific IgE antibodies on the surface of mast cells and basophils; in sensitized individuals, this interaction triggers the release of inflammatory mediators, resulting in a visible wheal-and-flare reaction. It is categorized as a diagnostic biological agent rather than a therapeutic medication and is listed in databases such as DrugBank (DB10923).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus resinosa pollen.